The Role of JAK Inhibitors in Closing Gaps in RA Management
Guidelines
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS, et al. Ann Rheum Dis. 2020;79(6):685-699.
2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.
Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.
Suggested Readings
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, et al. Lancet. 2017;390(10093):457-468.
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Strand V, et al. Arthritis Res Ther. 2015;17:362.
Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis.
Clowse MEB, et al. Drug Saf. 2016;39(8):755-762.
Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.
Pérez-Baos S, et al. Br J Pharmacol. 2017;174(18):3018-3031.
Baricitinib versus placebo or adalimumab in rheumatoid arthritis.
Taylor PC, et al. N Engl J Med. 2017;376(7):652-662.
Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment.
Fleischmann R, et al. Arthritis Rheumatol. 2017;69(3):506-517.
Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis.
Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 10):642-643. Abstract FRI0123.
Upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis: results at 72 weeks from SELECT-EARLY.
van Vollenhoven R, et al. Ann Rheum Dis. 2020;79(suppl 1):333-335. Abstract THU0217.
Long-term safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks from the SELECT-COMPARE study.
Fleischmann R, et al. Ann Rheum Dis. 2020;79(suppl 1):323. Abstract THU0201.
Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, randomized controlled phase 3 trial.
Rubbert-Roth A, et al. Ann Rheum Dis. 2020;79(suppl 1):1015-1016. Abstract SAT0151.
Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis.
Cohen SB, et al. Ann Rheum Dis. 2020;79(suppl 1):319-320. Abstract THU0197.
Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH 1 52-week results.
Combe B, et al. Ann Rheum Dis. 2020;79(suppl 1):320-321. Abstract THU0198.
Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis: FINCH 3 52-week results.
Westhovens R, et al. Ann Rheum Dis. 2020;79(suppl 1):1019-1020. Abstract SAT0158.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials.
Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 1):324-325. Abstract THU0202.
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R. Rheumatology (Oxford). 2019;58(suppl 1):i27-i33.
Efficacy and safety of switching Jakinibs in rheumatoid arthritis.
Retuerto-Guerrero M, et al. Ann Rheum Dis. 2020;79(suppl 1):648-649. Abstract FRI0132.
Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase.
Vallejo-Yagüe E, et al. Drug Saf. 2020;43(9):881-891.
Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value.
Institute for Clinical and Economic Review. October 11, 2019.
The Impact of Step-Therapy Policies on Patients
Snow J, et al. Xcenda AmerisourceBergen. December 4, 2019.
Treatment delays associated with prior authorization for infusible medications: a cohort study.
Wallace ZS, et al. Arthritis Care Res (Hoboken). 2019. [Epub ahead of print.]
Additional abstracts from EULAR 2020 E-Congress.
Additional abstracts from EULAR 2020 E-Congress. From June 3, 2020.
Clinician, Patient, and Caregiver Resources
Coalition of State Rheumatology Association (CSRO) Legislative Map Tool
The CSRO’s legislative map tool provides information about existing and pending step therapy, nonmedical switching, accumulator adjustment program, and uniform prior authorization laws by state and at the federal level.
American College of Rheumatology: Patient and Caregiver Resources
The ACR has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.
Arthritis Foundation
The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.
European League Against Rheumatism
EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.
NIH Health Topics: Rheumatoid Arthritis
A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about rheumatoid arthritis.
Module 1
Module 2
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Debates & Discussions on the Evolving Role of JAK Inhibitors
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
From Patient Evaluations to New Targeted Therapies
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
